Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

C-Type Natriuretic Peptide and Cardiovascular-Renal Protection in Sepsis.

Hypertension (Dallas, Tex. : 1979)·2026

Same author

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors.

British journal of pharmacology·2025

Same author

Effects of physiological doses of atrial natriuretic peptide on lipolysis, ketogenesis, and glucose metabolism in men.

American journal of physiology. Endocrinology and metabolism·2025

Same author

C-Type Natriuretic Peptide: Protecting the Aorta.

Arteriosclerosis, thrombosis, and vascular biology·2025

Same author

Significance of common genetic variants associated with non-ischaemic cardiomyopathy in the general population.

European journal of heart failure·2025

Same author

NPA7: A Dual Receptor Activating Peptide That Inhibits Cardiac Oxidative Stress.

Hypertension (Dallas, Tex. : 1979)·2025

Same journal

Mammalian Respiratory Chain Complex Assemblies and Their Links to Mitochondria Stress-Induced Human Diseases.

Advances in experimental medicine and biology·2026

Same journal

Enzyme Assemblies in Nucleotide Metabolism: Structure, Regulation, and Disease Implications.

Advances in experimental medicine and biology·2026

Same journal

The Pyruvate Dehydrogenase Complex: A 90-Year-Old Enigma Shaping the Future of Structural Enzymology.

Advances in experimental medicine and biology·2026

Same journal

Regulation of the Anti-termination RNA Transcription Complex by Lon-Mediated Lambda N Degradation.

Advances in experimental medicine and biology·2026

Same journal

PCNA Macromolecular Complexes: PCNA Serves as a Molecular Hub Regulating Multiple Cellular Processes Inside and Outside of the Nucleus.

Advances in experimental medicine and biology·2026

Same journal

Dynamic Assemblies in Genome Maintenance.

Advances in experimental medicine and biology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Aptamer-siRNA chimeras for HIV.

Mayumi Takahashi¹, John C Burnett, John J Rossi

¹Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, 1500 E Duarte Rd., Duarte, CA, 91010, USA, mtakahashi@coh.org.

Advances in Experimental Medicine and Biology

|March 12, 2015

Summary

This summary is machine-generated.

Aptamer-siRNA chimeras offer a novel therapeutic strategy for HIV-1, overcoming delivery challenges associated with small interfering RNA (siRNA) treatments. These engineered molecules target HIV-1 effectively, showing promise for future therapies.

More Related Videos

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

Related Experiment Videos

Last Updated: Apr 16, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

Area of Science:

Biotechnology
Molecular Biology
Virology

Background:

HIV/AIDS remains a global pandemic despite advances in combination antiretroviral therapy (cART).
Long-term cART use can lead to chronic health issues, necessitating alternative therapeutic approaches.
RNA interference (RNAi) using small interfering RNAs (siRNAs) presents a promising strategy for targeting previously undruggable targets, but faces delivery challenges.

Purpose of the Study:

To highlight the development and therapeutic potential of aptamer-siRNA chimeras for HIV-1 treatment.
To explore the use of aptamers for targeted delivery of siRNAs against HIV-1.
To review recent progress in engineering nucleic acids for targeted siRNA delivery.

Main Methods:

Development of aptamers using SELEX technology to target HIV-1 proteins and host factors.
Engineering of aptamer-siRNA chimeras for targeted delivery of therapeutic siRNAs.
Evaluation of aptamers targeting HIV-1 gp120 or CD4 for therapeutic applications.

Main Results:

Aptamers have been developed that exhibit potent viral neutralization and inhibition of HIV-1 infectivity.
Aptamer-siRNA chimeras have been designed and evaluated for HIV-1 treatment and prevention.
Progress in nucleic acid engineering facilitates targeted siRNA delivery via aptamers.

Conclusions:

Aptamer-siRNA chimeras represent a promising next-generation therapeutic approach for HIV-1.
Targeted delivery of siRNAs using aptamers overcomes a major hurdle in siRNA-based therapy.
Further development of aptamer-siRNA chimeras holds significant therapeutic potential for managing HIV-1 infection.